Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

In this article, we are going to take a look at where Kohls Corp (NYSE:KSS) stands against other stocks that Jim Cramer discussed recently. Jim Cramer kicked off his latest episode of Mad Money by ...

Watering is arguably the most important aspect in a peace lily's care regime. Only rehydrate the soil once the top third has dried out – check if the soil is dry by feeling the compost on top, and if ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

After swinging between gains and losses for most of the day, the Dow closed 0.5% higher, the S&P 500 gained 0.6% and the Nasdaq climbed 0.7% – though the three indices finished the week down ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.